Tone Frost Bathen is professor in Medicine (MR technology) at the Norwegian University of Science and Technology, Department of Circulation and Medical Imaging. Since the early 90-ties, Tone Frost Bathen has worked with the implementation of nuclear magnetic resonance techniques in cancer. As head of the MR Cancer group, her main research interests are focused towards personalized medicine and studies of functional and metabolic properties of cancer using magnetic resonance imaging (MRI) and spectroscopy (MRS). By developing, optimizing and applying advanced MR (in combination with other Omics-levels) to characterize cancer, the goal is to establish better diagnostic tools for stratification of patients to treatment, treatment monitoring and evaluation of prognosis. Current research activities mainly focus on breast and prostate cancer, enabled by a close collaboration with clinicians at the St. Olavs University Hospital in Trondheim. Although clinical research has high priority, a broad spectrum of systems for cancer studies provides translational research, covering ex vivo NMR as well as in vivo MR imaging and spectroscopy of cancer cells and laboratory animals. The MR cancer group maintains several large biobanks of human tissue and biofluid samples, and is internationally recognized for their large scale analyses of intact cancer biopsies. The research group is also involved in biomedical research related to cardiac heart disease, preeclampsia and testing of new contrast agents. Tone F. Bathen is Scientific vice-leader of the MR Core Facility at NTNU, and she is also academic responsible for a PhD course in metabolomics provided biannually at NTNU. Tone F. Bathen is a member of the Scientific Board of the Norwegian Cancer Society, she has a strong funding track record, and a large network of international collaborators.

Nils J. Færgeman is professor and director of the molecular metabolism and metabolomics unit at The Department of Molecular Biology and Biochemistry at University of Southern Denmark. He obtained his PhD degree in molecular cell biology in 1997 from University of Southern Denmark and after a post-doctoral period at Albany Medical College (Albany, NY, USA), he was recruited back to University of Southern Denmark, where he has been an independent PI since 2003. His research interests revolve around how metazoans sense alterations in the environment and in their genome and how they adapt metabolism to maintain cellular homeostasis, promote survival and achieve balanced growth. His group takes a systems biology-wide approach and combines genomics, proteomics and metabolomics to untangle novel mechanisms regulating metabolism. He has a particular interest in lipid metabolism and made several important contributions to understanding the functional role of lipid binding proteins and fatty acid transporters in fatty acid import, transport, metabolism and signaling.

Daniel Globisch is an Associate Professor in Analytical Pharmaceutical Chemistry and a SciLifeLab Fellow at Uppsala University. He received his PhD degree from the Ludwig-Maximilians-University Munich in Germany in 2011, where he quantified natural RNA/DNA modifications using mass spectrometric techniques. For his postdoctoral studies, he joined The Scripps Research Institute, La Jolla, CA (USA) working on bacterial quorum sensing and metabolomics analysis. During his 4,5 year stay Dr. Globisch discovered the urinary biomarker N-acetyltyramine-O-glucuronide (NATOG) using a metabolomics mining approach for the neglected tropical disease onchocerciasis, for which he developed an antibody-based urine dipstick test. He started leading his independent laboratory in September 2015 at Uppsala University after recruitment by the Science For Life Laboratory. Dr. Globisch’s research focus lies on the development of new Chemical Biology tools to enhance the scope of metabolomics research. His interdisciplinary research projects integrate global metabolomics, organic chemistry as well as Chemical Biology and are focused on elucidating the metabolic interaction between microbiota and their human host. He explores the potential of microbiota metabolism as a new strategy for the discovery of unknown biomarkers for pancreatic and colorectal cancer as well as unknown bioactive metabolites produced by the gut microbes.

Kati Hanhineva (serving second term), PhD, is professor of food development, with special focus on Nordic foods and health effects at the University of Turku, Department of Biochemistry, Food Chemistry and Food Development unit. Her main research focus is within the biochemistry of foods, especially phytochemical compounds and the effect of food processing on their composition. Likewise, molecular level understanding of the role of nutrition in maintaining good health, and food-microbiota interaction are within the core of her research. The key analytical technology at the different stages of research is the mass-spectrometry based metabolic profiling that she has developed and utilized for various food and nutrition related applications, in particular within projects related to the beneficial health effect of whole grain rich diets. Dr. Hanhineva has completed her PhD in plant biotechnology at the University of Kuopio 2008, and conducted post-doctoral research at the Department of Public Health and Clinical Nutrition, with several research visits to the Weizmann Institute of Science in Israel. Currently she holds also Research director position at University of Eastern Finland, Kuopio, and is affiliated as visiting scientist at the Chalmers University of Technology, Gothenburg, Sweden.

Katharina Herzog (early-career member) obtained a PhD in biomedicine as a Marie Curie Early Stage Researcher at the Academic Medical Center (University of Amsterdam). Her long-standing research interests are the increased understanding of human metabolism, with a focus on prevention, diagnosis, and clinical perspectives of human metabolic diseases. Other key interests are the application of metabolomics, bioinformatics tools, and data integration for patient-oriented research. During her PhD, Katharina performed functional lipidomics studies and investigated novel biomarkers in samples from patients with a peroxisomal disorder. As a postdoctoral researcher, Katharina translated her research interests into the field of diabetes. At Lund University, Katharina studied the effect of interventions such as diet and gastric bypass surgery on the plasma metabolome. Since October 2019, Katharina pursues a Novo Nordisk postdoctoral fellowship within the Institute of Environmental Medicine at the Karolinska Institute, studying the prognostic role of environmental, metabolic, and clinical factors in a hybrid form of diabetes. Since 2018, Katharina is a committee member of the early-career member network (EMN) of the Metabolomics Society.

Rikard Landberg (serving second term) is a professor of food and Health at Chalmers University of Technology where he is heading the Division Food and Nutrition Science at the Department of Biology and Biological Engineering. His group studies the role of diet and dietary components in health and disease using observational and intervention studies as well as in various model systems. Metabolomics (MS- and NMR- techniques) has become a center point of the research for discovery and validation of exposure and prediction biomarkers, and currently, for molecular phenotyping to discover biomarkers to guide (dietary) intervention individualization strategies. The group is engaged in several large national and international cohort studies and infrastructures where they generate metabolomics data from thousands of individuals to address different research questions in nutrition and medicine. RL is also the principle investigator of randomized controlled trials to evaluate health effects of various food components in a precision nutrition approach. RL is affiliated Professor at the Department of Public Health and Clinical Medicine at Umeå University and a visiting scientist at Danish Cancer Society Research Center in Copenhagen and at the Nutritional Epidemiology Unit at the Institute of Environmental Medicine, Karolinska Institutet. RL has authored/co-authored ~95 papers, ~10 book chapters, delivered ~10 invited lectures and is the editor of one book. RL has an H-index of 25 according to Scopus.

Matej Orešič (serving second term; acting chairman of the board) holds a PhD in biophysics from Cornell University (NY, USA). He is professor of medical sciences with specialization in systems medicine at the Örebro University (Sweden), group leader in systems medicine at the Turku Bioscience Centre (Finland), and guest professor in lipids and nutrition at the Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences (Wuhan, P.R. China). As of 2016, Prof. Orešič is a Lifetime Honorary Fellow of the Metabolomics Society. In 2019, he was co-chair of the 1st Gordon Research Conference on 'Metabolomics and Human health'. His main research areas are metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities, with main focus on type 1 diabetes and non-alcoholic fatty liver disease. Prof. Orešič also initiated the MZmine project, leading to a popular open source software for metabolomics data processing.

Óttar Rolfsson (serving second term) holds a PhD from the Astbury Center of Structural Molecular Biology at The University of Leeds. He is an Assistant Professor in Biochemistry and Molecular Biology within the Medical Department and within the Center for Systems Biology at the University of Iceland. Óttar teaches human metabolism and systems biology to all students within the Health Sciences Department at UI. Work within the Rolfsson laboratory is focused on understanding how molecular metabolism contributes to health and disease through mass spectrometry metabolomics approaches and cell scale metabolic modelling. The groups main focus at present is elucidating red cell and platelet metabolism in the context of transfusion medicine and investigating metabolic changes associated with disease related cellular developmental events including epithelial to mesenchymal transition, mesenchymal stem cell development and endothelial dysfunction.

Craig Wheelock (serving second term) leads the Integrative Molecular Phenotyping laboratory at the Karolinska Institute and is a Distinguished Visiting Professor of Metabolomics at the Gunma Institute for Advanced Research (GIAR) at Gunma University, Japan. His research focuses on mass spectrometry-based molecular phenotyping of obstructive lung disease. These efforts are combined with multivariate modelling to perform omics-based data integration to identify sub-phenotypes of disease. A major area of the research in his group centers on investigating the role of lipid mediators in pulmonary inflammation. Recent efforts involve performing exposome-based studies to understand the effect of environmental exposure upon disease etiology and identify sensitive sub-populations of individuals with respiratory disease. The overall aim of the work in his group is to develop personalized molecular profiles that can be associated with an individual’s lifestyle, environmental exposure and susceptibility to disease onset. Dr. Wheelock is a member of the European Respiratory Society (ERS) Scientific Events Working Group, Board Member of the International Metabolomics Society, and consultant at the Mount Sinai School of Medicine on metabolomics and the exposome.